<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>TMVR</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>New York Valves: More options, more valves</title>
      <description>
        <![CDATA[Aortic valve repair and replacement continue to grab attention appropriate for the number of people affected, but the heart’s other three valves are finally gaining some respect as med-tech companies and analysts recognize the size of the potential total addressable market.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721616</guid>
      <pubDate>Tue, 01 Jul 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721616-new-york-valves-more-options-more-valves</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/09-21-tricuspid-regurgitation.webp?t=1663801036" type="image/png" medium="image" fileSize="768871">
        <media:title type="plain">tricuspid regurgitation</media:title>
      </media:content>
    </item>
    <item>
      <title>Edwards lands first CE mark for transfemoral mitral valve replacement</title>
      <description>
        <![CDATA[Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery or transcatheter edge-to-edge repair. Sapien M3 is indicated for individuals with symptomatic moderate-to-severe or severe mitral valve regurgitation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/719123</guid>
      <pubDate>Mon, 14 Apr 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/719123-edwards-lands-first-ce-mark-for-transfemoral-mitral-valve-replacement</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Sapien_M3-14apr25.webp?t=1766528025" type="image/jpeg" medium="image" fileSize="195288">
        <media:title type="plain">Edwards Lifesciences Sapien M3</media:title>
        <media:description type="plain">Edwards Lifesciences SAPIEN M3 Transcatheter Mitral Valve Replacement System. Credit: Edwards Lifesciences Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>4C raises $175M for mitral valve technology</title>
      <description>
        <![CDATA[4C Medical Technologies Inc. raised $175 million in a series D financing round led by Boston Scientific Corp. The financing will support the regulatory trials and commercialization of the Altavalve system, a transcatheter mitral valve replacement (TMVR) technology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717735</guid>
      <pubDate>Thu, 06 Mar 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717735-4c-raises-175m-for-mitral-valve-technology</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardio-heart-mitral-valve.webp?t=1611181711" type="image/png" medium="image" fileSize="397941">
        <media:title type="plain">3D rendering of heart, mitral valve</media:title>
      </media:content>
    </item>
    <item>
      <title>TMVR technologies coming, but challenges remain</title>
      <description>
        <![CDATA[Although there is a clear clinical need for transcatheter mitral valve replacement technologies, a number of challenges must be overcome before they can safely be used to treat patients with mitral regurgitation. Nevertheless, two new devices could enter the European market next year, Edwards Lifesciences Corp.’s Sapien M3 and Highlife Medical SAS’s Highlife TMVR device.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714502</guid>
      <pubDate>Tue, 26 Nov 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714502-tmvr-technologies-coming-but-challenges-remain</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardio-heart-mitral-valve.webp?t=1611181711" type="image/png" medium="image" fileSize="397941">
        <media:title type="plain">3D rendering of heart, mitral valve</media:title>
      </media:content>
    </item>
    <item>
      <title>Edwards wins support for TTVR device Medicare coverage proposal</title>
      <description>
        <![CDATA[Edwards Lifesciences Corp. made a splash recently with the U.S. FDA approval of the Evoque tricuspid valve replacement device, but is also pressing Centers for Medicare and Medicaid Services to provide a coverage framework for this class of devices.]]>
      </description>
      <guid>http://www.bioworld.com/articles/712910</guid>
      <pubDate>Mon, 07 Oct 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/712910-edwards-wins-support-for-ttvr-device-medicare-coverage-proposal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/EVOQUE-02feb24.webp?t=1706907066" type="image/jpeg" medium="image" fileSize="57277">
        <media:title type="plain">Edwards EVOQUE</media:title>
        <media:description type="plain">The Evoque system is indicated for the improvement of health status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy.</media:description>
      </media:content>
    </item>
    <item>
      <title>Edwards buying Innovalve Bio Medical for $300M</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Edwards Lifesciences Corp. said it has exercised its option to buy Innovalve Bio Medical Ltd., an early stage transcatheter mitral valve replacemen company, for $300 million in cash following its initial investment in 2017.  Since that time, Edwards said Innovalve has demonstrated progress in its program with promising early clinical experience.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710286</guid>
      <pubDate>Mon, 15 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710286-edwards-buying-innovalve-bio-medical-for-300m</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Acquisition-puzzle.webp?t=1682968589" type="image/jpeg" medium="image" fileSize="193595">
        <media:title type="plain">Acquisition puzzle</media:title>
      </media:content>
    </item>
    <item>
      <title>Edwards invests €15M in Affluent’s heart products</title>
      <description>
        <![CDATA[Edwards Lifesciences Inc. struck three deals totaling €15 million (US$16.3 million) with Affluent Medical SAS to gain access to its mitral valve technology. Edwards secured an exclusive option to acquire Affluent subsidiary Kephalios, which makes the Kalios adjustable mitral ring, for €5 million (US$5.44 million); paid €5 million more for global, non-exclusive licensing of Affluent’s intellectual property related to its biomimetic cardiac mitral valve replacement technology; and invested a further €5 million to acquire 9.21% of Affluent.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709999</guid>
      <pubDate>Fri, 12 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709999-edwards-invests-15m-in-affluents-heart-products</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/kalios-12july24.webp?t=1720820008" type="image/jpeg" medium="image" fileSize="65054">
        <media:title type="plain">Edwards Affluent Kalios</media:title>
        <media:description type="plain">Affluent Medical’s Kalios adjustable mitral ring. Credit: Affluent Medical</media:description>
      </media:content>
    </item>
    <item>
      <title>Cardiomech injects $13M into mitral valve tech</title>
      <description>
        <![CDATA[Cardiomech AS raised $13 million in fresh capital via a convertible loan agreement that will go towards developing its transcatheter mitral valve chordal repair technology. The round was heavily oversubscribed, indicating investors' expectations that the company’s technology may be a first-line therapy for patients suffering from degenerative mitral regurgitation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704002</guid>
      <pubDate>Fri, 05 Jan 2024 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704002-cardiomech-injects-13m-into-mitral-valve-tech</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Coin-stacks-layered-with-charts.webp?t=1704490718" type="image/jpeg" medium="image" fileSize="279631">
        <media:title type="plain">Coin stacks layered with charts</media:title>
      </media:content>
    </item>
    <item>
      <title>Innovheart seals $55M financing deal for Saturn TMVR device</title>
      <description>
        <![CDATA[Innovheart srl has landed more than $55 million to continue clinical trials of its transcatheter mitral valve replacement (TMVR) system for the treatment of mitral valve disease. The series C equity round was led by Grand Pharmaceutical Group Ltd. (Grand Pharma), together with existing investors Genextra, Panakes Partners and Indaco Venture Partners.]]>
      </description>
      <guid>http://www.bioworld.com/articles/515569</guid>
      <pubDate>Fri, 28 Jan 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/515569-innovheart-seals-55m-financing-deal-for-saturn-tmvr-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardio-heart-mitral-valve.webp?t=1611181711" type="image/png" medium="image" fileSize="397941">
        <media:title type="plain">3D rendering of heart, mitral valve</media:title>
      </media:content>
    </item>
    <item>
      <title>EU greenlights Abbott’s transcatheter mitral valve replacement device</title>
      <description>
        <![CDATA[Abbott Laboratories has received CE mark approval for its Tendyne transcatheter mitral valve implantation (TMVI) system, the first such device approved for use in Europe and the world. The system is intended for patients with leaky mitral valves that are beyond repair and those at high risk for open heart surgery.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432746</guid>
      <pubDate>Thu, 30 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432746-eu-greenlights-abbotts-transcatheter-mitral-valve-replacement-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/1-30-Abbott-Tendyne.webp?t=1580424350" type="image/png" medium="image" fileSize="202247">
        <media:title type="plain">1-30-Abbott-Tendyne.png</media:title>
        <media:description type="plain">Tendyne transcatheter mitral valve implantation system.
Credit: Abbott Laboratories</media:description>
      </media:content>
    </item>
    <item>
      <title>Doctors ink mitral valve repair guidelines as CMS eyes Mitraclip coverage</title>
      <description>
        <![CDATA[While the U.S. Centers for Medicare and Medicaid Services (CMS) revisits its coverage policy for transcatheter mitral valve repair devices, several physician societies have drafted recommendations for operator and institutional volume requirements that could restrict the number of centers authorized to practice devices such as Abbott Park, Ill.-based Abbott Laboratories&rsquo; Mitraclip.]]>
      </description>
      <guid>http://www.bioworld.com/articles/431832</guid>
      <pubDate>Mon, 16 Dec 2019 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/431832-doctors-ink-mitral-valve-repair-guidelines-as-cms-eyes-mitraclip-coverage</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2019/Abbott-MITRACLIP-12-16.webp?t=1576537782" type="image/png" medium="image" fileSize="955247">
        <media:title type="plain">Abbott-MITRACLIP-12-16.png</media:title>
        <media:description type="plain">Mitraclip device. Credit: Abbott Laboratories</media:description>
      </media:content>
    </item>
    <item>
      <title>Abbott unveils positive data on Mitraclip, Triclip</title>
      <description>
        <![CDATA[Abbott Laboratories had a busy Transcatheter Cardiovascular Therapeutics (TCT) 2019 conference. Among the news it generated was the unveiling of new analyses of the COAPT trial on the cost-effectiveness of Mitraclip vs. guideline-directed medical therapy (GDMT) alone in heart failure patients with secondary mitral regurgitation (MR).]]>
      </description>
      <guid>http://www.bioworld.com/articles/430053</guid>
      <pubDate>Tue, 01 Oct 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430053-abbott-unveils-positive-data-on-mitraclip-triclip</link>
    </item>
  </channel>
</rss>
